论文部分内容阅读
目的：探讨oltipraz对人肺早期癌变是否有阻断作用及其作用的分子机制。方法：人胚肺组织培养，光镜病理检查、ELISA法分析GST-π蛋白含量，比色法测GSTs活性，免疫组化分析mP53基因表达。结果：病理分析显示oltipraz阻断人肺早期癌变在CSC运用前或同时运用效果较好；测GST-π含量CSC组为129．2±26．9，CSC／oltipraz组为80．3±12．7，DMSO组为79．5±15．5（ng／mgprotein），试验组与对照组差别明显（P＜0．05）；GSTs活性也有类似效果；组织mP53基因表达CSC组为阳性，DMSO组为阴性，CSC／oltipraz组多为弱阳性。结论：oltipraz对人肺早期癌变有较好的阻断作用，它能使GST-π、mP53基因表达减弱。
Objective: To explore the molecular mechanism of oltipraz in the early stage of human lung cancer. Methods: Human embryonic lung tissue culture, light pathological examination, ELISA method were used to analyze the content of GST-π protein. Colorimetric method was used to measure GSTs activity. Immunohistochemistry was used to analyze the expression of mP53 gene. RESULTS: Pathological analysis showed that oltipraz blocked the early stage of lung cancer in patients with CSC before or at the same time. The GST-π content in the CSC group was 129.2±26.9, and the CSC/oltipraz group was 80.3±12. 7, DMSO group was 79.5±15.5 (ng/mg protein), the difference between experimental group and control group was significant (P<0.05); GSTs activity had similar effect; tissue mP53 gene expression was positive in CSC group, DMSO group If negative, the CSC/oltipraz group is mostly weakly positive. Conclusion: Oltipraz has a good blocking effect on the early stage of human lung cancer, it can make the GST-π, mP53 gene expression weakened.